Tasigna’s sales will rise of course but I think short term more on the expanse of Sprycel in 2nd line. Anyhow NVS has time to move Tasigna into 1st line before Gleevec goes off patent in 2015.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.